Page last updated: 2024-11-05

hexylcaine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hexylcaine is a local anesthetic that is structurally related to benzocaine. It is used for pain relief in topical applications. Hexylcaine is a synthetic compound that is produced by reacting a halogenated aromatic compound with an appropriate amine. Hexylcaine has a rapid onset of action and a moderate duration of action. It is primarily used for pain relief in the treatment of minor skin conditions, such as burns, abrasions, and insect bites. Hexylcaine is often studied to improve its effectiveness and safety, particularly in the area of topical pain relief. Research is focused on developing novel formulations and optimizing its pharmacokinetic properties.'

hexylcaine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10770
CHEMBL ID1197
CHEBI ID34791
SCHEMBL ID34238
MeSH IDM0046190

Synonyms (38)

Synonym
BRD-A97730597-003-03-2
hexylcaine
1-(cyclohexylamino)-2-propanol benzoate (ester)
PRESTWICK2_000788
532-77-4
BPBIO1_000986
hexylcainum [inn-latin]
2-propanol, 1-(cyclohexylamino)-, benzoate (ester)
(2-cyclohexylamino-1-methylethyl) benzoate
hexilcaina [inn-spanish]
hexylcaine [inn]
NCGC00179382-01
PRESTWICK3_000788
BSPBIO_000896
AB00514688
DB00473
PRESTWICK1_000788
SPBIO_002835
PRESTWICK0_000788
1-(cyclohexylamino)propan-2-yl benzoate
osmocaine
chebi:34791 ,
CHEMBL1197
benzoic acid 2-cyclohexylamino-1-methyl-ethyl ester
unii-511iu0826z
hexilcaina
hexylcainum
511iu0826z ,
hexylcaine [who-dd]
gtpl7196
SCHEMBL34238
DTXSID1047863
2-(cyclohexylamino)-1-methylethyl benzoate #
hexylcainc
Q5749095
bdbm50225698
cyclain; osmocaine
EN300-25300387
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID450269Displacement of [3H]-BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Ligand-based design and synthesis of novel sodium channel blockers from a combined phenytoin-lidocaine pharmacophore.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID450273Lipophilicity, log P of the compound2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Ligand-based design and synthesis of novel sodium channel blockers from a combined phenytoin-lidocaine pharmacophore.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (93.33)18.7374
1990's0 (0.00)18.2507
2000's1 (3.33)29.6817
2010's1 (3.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.01 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]